Adaptive Biotechnologies Corporation Common Stock Earnings Dividend

Adaptive Biotechnologies Corporation Common Stock’s revenue jumped 35.14% since last year same period to $70.87Mn in the Q1 2026. On a quarterly growth basis, Adaptive Biotechnologies Corporation Common Stock has generated -1.13% fall in its revenue since last 3-months.

Adaptive Biotechnologies Corporation Common Stock’s net profit jumped 32.89% since last year same period to $-20.03Mn in the Q1 2026. On a quarterly growth basis, Adaptive Biotechnologies Corporation Common Stock has generated -47.53% fall in its net profits since last 3-months.

Adaptive Biotechnologies Corporation Common Stock’s net profit margin jumped 50.34% since last year same period to -28.27% in the Q1 2026. On a quarterly growth basis, Adaptive Biotechnologies Corporation Common Stock has generated -49.21% fall in its net profit margins since last 3-months.

Adaptive Biotechnologies Corporation Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.13 - a 18.75% jump from last quarter’s estimates.

Adaptive Biotechnologies Corporation Common Stock’s earning per share (EPS) estimates for the current year stand at -0.13.

Adaptive Biotechnologies Corporation Common Stock’s earning per share (EPS) jumped 35% since last year same period to -0.13 in the Q1 2026. This indicates that the Adaptive Biotechnologies Corporation Common Stock has generated 35% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Adaptive Biotechnologies Corporation Common Stock’s return on assets (ROA) stands at -0.06.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Adaptive Biotechnologies Corporation Common Stock’s return on equity (ROE) stands at -0.24.